Docteur Oswald VAN CUTSEM Pneumologue Chef de Service

Size: px
Start display at page:

Download "Docteur Oswald VAN CUTSEM Pneumologue Chef de Service"

Transcription

1 Docteur Oswald VAN CUTSEM Pneumologue Chef de Service Contacts secrétariat planning : secrétariat consultations : Diplômes : Doctorat UCL 1983 Diplôme de spécialiste en pneumologie UCL 1988 Mandats Membre de l European Lung Cancer Working Party Membre de la Société Belge de Pneumologie Membre de la Société de Pathologie Thoracique du Nord (France) Membre de la Société de Pneumologie de langue française Membre de l European Respiratory Society Publications VAN CUTSEM O., REMY J., WALLAERT B., TONNEL A.B. Fièvre, douleur et cavité. Rev. Mal. Resp. 1988, 5, 81-83

2 VAN CUTSEM O., MERRILL W.W. Aerobic gram positive infections Current Therapy Disease B.C. Deckers Inc. Toronto. Philadelphia R.M. Cherniak, 372 pages VAN CUTSEM O.,, LEDENT C., MAIRESSE M. Le granulome hyalinisant du poumon. Rev. Mal. Resp. 1990, 7, SCULIER J.-P., PAESMANS M., BUREAU G., DABOUIS G., LIBERT P., VANDERMOTEN G., VAN CUTSEM O., BERCHIER M.-C., RIES F., MICHEL J., SERGYSELS R., MOMMEN P., KLASTERSKY J. Une chimiothérapie hebdomadaire avec de multiples médicaments ou un traitement de chimiothérapie standard : résultats d une étude phase III conduite dans le cancer bronchique à petites cellules par l European Lung Cancer Working Rev. Mal. Resp. 1994, 11 : KLASTERSKY J., SCULIER J.-P., RIES F., DABOUIS G., LIBERT P., SCHMERBER J., THIRIAUX J., BERCHIER M.-C., BUREAU G., VAN CUTSEM O., TAGNON A., SERGYSELS R., MOMMEN P., PAESMANS M. for the European Lung Cancer Working party. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5- fluorouracil. Annals of Oncology 1994, 5 : SCULIER J.-P., PAESMANS M., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J., VAN CUTSEM O., SCHMERBER J., GINER V., VERCHIER M.-C., SERGYSELS R., MOMMEN P., KLASTERSKY J. for the European Lung Cancer Working party. Long-term survival after chemotherapy containing platinum derivatives in patient with advanced unresectable non small cell lung cancer. Eur. J. Cancer. 1994, 30A : KLASTERSKY J., SCULIER J.-P., RIES F., DABOUIS G., LIBERT P., SCHMERBER J., THIRIAUX J., BERCHIER M.-C., BUREAU G., VAN CUTSEM O., TAGNON A., SERGYSELS R., MOMMEN P., PAESMANS M. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile : a regimen associated with majour toxicity in patients with advance non-small cell lung cancer. SCULIER J.-P., BUREAU G., GINER V., THIRIAUX J., MICHEL J., BERCHIER M.-C., VAN CUTSEM O., KÜSTNER U., KROLL F., MOMMEN P., PAESMANS M., KLASTERSKY J. Induction chemotherapy with ifosfamide, etoposide, ans anthracycline for small cell lung. Experience of the European Lung Cancer Working Sem. Oncol (suppl.2) :

3 PAESMANS M., SCULIER J.-P., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J., VAN CUTSEM O., SERGYSELS R., MOMMEN P., KLASTERSKY for the European Lung Cancer Working party. Prognostic factors for survival in advance non small cell lung cancer ; uni-and multivariate analyses including recpam analysis in 1052 patients. J. Clin. Oncol : Update pour Classic Papers and Current Comments : 1997, 2 (1) : (Highlights of lung cancer research). SCULIER J.-P., PAESMANS M., BUREAU G., GINER V., LECOMPTE J., MICHEL J., BERCHIER M.-C., VAN CUTSEM O., KÜSTNER U., KROLL F., SERGYSELS R., MOMMEN P., KLASTERSKY Y. for the European Lung Cancer Working A randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small cell cancer. J. Clin. Oncol. 1996, 14 : BORGES M., SCULIERS J.-P., PAESMANS M., LIBERT P., BUREAU G., DABOUIS L., THIRIAUX J., MICHEL J., VAN CUTSEM O., SCHMERBER J., GINER V., BERCHIER M.-C., SERGYSELS R., MOMMEN P., KLASTERSKY J. for the European Lung Cancer Working Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC) Lung Cancer 1996, 16 :21-33 PAESMANS M., SCULIER J.-P., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J., VAN CUTSEM O., SERGYSELS R., MOMMEN P and KLASTERSKY J. for the European Lung Cancer Working Response to chemotherapy has a discriminant value on the distribution of further survival for patients with advanced non small cell lung cancer : a ten experience of the European lung Cancer Working Eur. J. Cancer 1997, 33 : SCULIER J.-P., PAESMANS M., NINANE V., GINER V., BUREAU G., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., VAN HOUTTE P., KLASTERSKY J., the European Lung Cancer Working Les facteurs pronostiques des cancers bronchiques non à petites cellules au stade avancé : l expérience de l European Lung Cancer Working Rev.. Mal. Resp. 1997, 14 : PAESMANS M., SCULIER J.-P., LECOMPTE J., THIRIAUX J., LIBERT P., SERGYSELS R., BUREAU G., DABOUIS G., VAN CUTSEM O., MOMMEN P., NINANE V., KLASTERSKY J, for the European Lung Cancer Working Prognostic factors for patients with small cell lung cancer : long-term experience of the European Lung Cance Working In «Cancers bronchopulmonaires» (MILLERON B., DEPIERE A.), ARNETTE, VELIZY- VILLACOUBLAY, 1998, pp SCULIER J.-P., PAESMANS M., NINANE V., GINER V., BUREAU G., LAFITTE J.-J. BAUMOHL J., THIRIAUX J., CAN CUTSEM O., RECLOUX P., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., VAN HOUTTE P., KLASTERSKY J., the European Lung Cancer Working

4 Evaluation of the TN sub-staging in patients with initially unresectable stage III non small cell lung cancer treated by induction chemotherapy. Lung cancer, 1998, 22 : SCULIER J.-P., PAESMANS M., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BUREAU G., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., BOSSCHAERTS T., BERGHMANS T., VAN HOUTTE P., NINANE V., KLASTERSKY J. - the European Lung Cancer Working A randomised phase III trial comparing further chemotherapy to chest irradiation in objectively responding patients with initially unresectable locoregional non-small cell lung cancer treated by induction chemotherapy. Annals of Oncology : SCULIER J.-P., PAESMANS M., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BUREAU G., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., BOSSCHAERTS T., BERGHMANS T., VAN HOUTTE P., NINANE V., KLASTERSKY J. - the European Lung Cancer Working Prognostic factors analysis for response to chemotherapy and survival in a prospective cohort of patients with unresectable locoregional non small cell lung cancer initially treated by induction chemotherapy. Rev. Oncologia 1999, 1, PAESMANS M., SCULIER J.-P., LECOMTE J., THIRIAUX J., LIBERT P., SERGYSELS R., BUREAU G., DABOUIS G., VAN CUTSEM O., MOMMEN P., NINANE V., KLASTERSKY J. for the European Lung Cancer Working Prognostic factors for pataients with small cell lung cancer : analysis of a serie of 763 patients included in 4 consecutive pospective trials and with a minimum follow-up of 75 years. Cancer 2000, 89 : SCULIER J.-P., PAESMANS M., LECOMTE J., VAN CUTSEM O., LAFITTE J.-J., BERGHMANS T., KOUMAKIS G., FLORIN M.-C., THIRIAUX J., MICHEL J., GINER V., BERCHIER M.-C., MOMMEN P., NINANE V., KLASTERSKY J. for the European Lung Cancer Working A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer 2001, 88 : SCULIER J.-P., BERGHMANS T, LAFITTE J.-J., RICHEZ M., RECLOUX P., VAN CUTSEM O., NINANE V., MOMMEN P., PAESMANS M., KLASTERSKY J. for the European Lung Cancer Working A phase III study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung cancer, :

5 SCULIER J.-P, LAFITTE J.-J., LECOMTE J., BERGHMANS T., THIRIAUX J., VAN CUTSEM O., EFREMIDIS A., NINANE V., PAESMANS M., MOMMEN P., KLASTERSKY for the European Lung Cancer Working A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Annals of Oncology, 2002,

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Small-Cell Lung Cancer: Is There a Standard Therapy?

Small-Cell Lung Cancer: Is There a Standard Therapy? Small-Cell Lung Cancer: Is There a Standard Therapy? Review Article [1] January 02, 1998 By Pieter E. Postmus, MD, PhD [2] and Egbert F. Smit, MD [3] For more than 25 years, chemotherapy has been the cornerstone

More information

Review. The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC)

Review. The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC) Annals of Oncology 10 (Suppl. 5): S13-S17,1999. 1999 Kluwer Academic Publishers. Printed in the Netherlands. Review The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC) A. Ardizzoni,

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Stage IIIB disease includes patients with T4 tumors,

Stage IIIB disease includes patients with T4 tumors, Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer* James R. Jett, MD, FCCP; Walter J. Scott, MD, FCCP; M. Patricia Rivera MD, FCCP; and William T. Sause, MD, FACR Stage IIIB includes patients

More information

Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer

Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer CLINICAL STUDY Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer Ahmet Bircan, MD 1 ; M. Bahad r Berktafl, MD 1 ; Hülya Bay z, MD 1 ; Nihal Baflay, MD 1 ; Sema Bircan, MD 2 ; Mine

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction: Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer

More information

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1 COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize

More information

Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board

Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board Abstract Introduction Management of stage III non small-cell lung cancer (NSCLC) is complex and requires careful work-up, staging,

More information

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)

More information

More than half of all lung cancer patients present with. New Combinations in the Treatment of Lung Cancer* A Time for Optimism

More than half of all lung cancer patients present with. New Combinations in the Treatment of Lung Cancer* A Time for Optimism New Combinations in the Treatment of Lung Cancer* A Time for Optimism Paul A. Bunn, Jr., MD; and Karen Kelly, MD Strides have been made in the treatment of lung cancer in the last decade that warrant a

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? British Journal of Cancer (04) 90, 1905 1911 All rights reserved 0007 09/04 $25.00 www.bjcancer.com Do patients with weight have a worse outcome when undergoing chemotherapy for lung cancers? PJ Ross 1,

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy

The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy 17 (Supplement 10): x108 x112, 2006 doi:10.1093/annonc/mdl247 The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy E. Felip & E. Vilar Oncology Department, Vall d

More information

Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer

Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,

More information

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Cancer de Primitif Inconnu (CAPI)

Cancer de Primitif Inconnu (CAPI) Cancer de Primitif Inconnu (CAPI) Cancer of Unknown Primary origin (CUP) Vincent Berry (Lille) 23/01/2015 Dirigé par le Dr PENEL Définitions Définitions Epidémiologie Anatomo pathologie Explorations Pronostic

More information

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,

More information

Lung Cancer - Combination Chemotherapy and the Risk of Failure

Lung Cancer - Combination Chemotherapy and the Risk of Failure Evidence-based Series 7-13-1 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Role of Combination Chemotherapy in the Initial Management of Limited-Stage

More information

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

Report on New Patented Drugs - Alimta

Report on New Patented Drugs - Alimta Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive

More information

4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used:

4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used: 4.8 Lung cancer 4.8.1 In 2005, both NICE (National Institute for Health and Clinical Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) published guidelines on the management of lung cancer.

More information

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer Evidence-based Series #7-12 Version 2 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Altered Fractionation of Radical Radiation Therapy in the Management of

More information

Thrombose associée au cancer. Prévention et traitement. Guy Meyer Université Paris Descartes Hopital Europeen Georges Pompidou, Paris, France

Thrombose associée au cancer. Prévention et traitement. Guy Meyer Université Paris Descartes Hopital Europeen Georges Pompidou, Paris, France Thrombose associée au cancer Prévention et traitement Guy Meyer Université Paris Descartes Hopital Europeen Georges Pompidou, Paris, France Conflits d intérêt G Meyer Investigateur: Bayer, Daichi-Sankyo,

More information

SECOND-LINE CHEMOTHERAPY in advanced non

SECOND-LINE CHEMOTHERAPY in advanced non Gemcitabine as Second-Line Treatment for Advanced Non Small-Cell Lung Cancer: A Phase II Trial By Lucio Crinò, Anna Maria Mosconi, Giorgio Scagliotti, Giovanni Selvaggi, Silvia Novello, Massimo Rinaldi,

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer?

Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Original Article Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Rajappa S, Gundeti S, Uppalapati S, Jiwatani S, Abhyankar A, Pal C,

More information

Targeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014

Targeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014 Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!

More information

What is the reference cytotoxic regimen in advanced gastric cancer?

What is the reference cytotoxic regimen in advanced gastric cancer? What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Key words: chemotherapy; evidence-based medicine; guidelines; non-small cell lung cancer

Key words: chemotherapy; evidence-based medicine; guidelines; non-small cell lung cancer Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer* Mark A. Socinski, MD, FCCP; David E. Morris, MD; Gregory A. Masters, MD, FCCP; and Rogerio Lilenbaum, MD Stage IV non-small cell lung

More information

Second-Line Chemotherapy

Second-Line Chemotherapy 40 Second-Line Chemotherapy Nick Pavlakis and Nicholas J. Vogelzang Chemotherapy trials for malignant pleural mesothelioma have almost exclusively focused on chemotherapy-naive patients. Until 2000, the

More information

Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer

Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer Michael Stokes United BioSource Corporation ISPOR 13 th Annual International Meeting Toronto,

More information

First- and second-line therapy for advanced nonsmall cell lung cancer

First- and second-line therapy for advanced nonsmall cell lung cancer Eur Respir J 2009; 33: 915 930 DOI: 10.1183/09031936.00132008 CopyrightßERS Journals Ltd 2009 SERIES LUNG CANCER Edited by C. Brambilla Number 4 in this Series First- and second-line therapy for advanced

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

Treatment of Advanced Non Small-Cell Lung Cancer: A Review of Current Randomized Clinical Trials and an Examination of Emerging Therapies

Treatment of Advanced Non Small-Cell Lung Cancer: A Review of Current Randomized Clinical Trials and an Examination of Emerging Therapies Progress in the treatment of advanced non small-cell lung cancer allows patients to live longer and with better quality of life. Milton Rochman. Mother s Comfort. Acrylic on canvas, 24 30. Courtesy of

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

Treatment of Small Cell Lung Cancer

Treatment of Small Cell Lung Cancer Chapter 5 Treatment of Small Cell Lung Cancer Ariel Lopez-Chavez MD, MS Introduction There are two main types of lung cancer, non-small cell lung cancer and small cell lung cancer. 1 It is important that

More information

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

INTRODUCTION. liver neoplasms, adrenal gland neoplasms, non small-cell lung cancer, radionuclide imaging, bisphosphonates,

INTRODUCTION. liver neoplasms, adrenal gland neoplasms, non small-cell lung cancer, radionuclide imaging, bisphosphonates, VOLUME 22 NUMBER 2 JANUARY 15 2004 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E American Society of Clinical Oncology Treatment of Unresectable Non Small-Cell Lung Cancer Guideline:

More information

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the

More information

clinical practice guidelines

clinical practice guidelines clinical practice guidelines Annals of Oncology 21 (Supplement 5): v120 v125, 2010 doi:10.1093/annonc/mdq172 Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

More information

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Special Article. Received 5 December 2014; revised 18 February 2015; accepted 25 February 2015. Practical Radiation Oncology (2015) 5, 141-148

Special Article. Received 5 December 2014; revised 18 February 2015; accepted 25 February 2015. Practical Radiation Oncology (2015) 5, 141-148 Practical Radiation Oncology (2015) 5, 141-148 www.practicalradonc.org Special Article Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society

More information

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012 Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically

More information

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total

More information

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)

More information

Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based

Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Cetuximab INDICATION: chemotherapy Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based COMPENDIA

More information

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data Preoperative for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data NSCLC Meta-analysis Collaborative Group* Summary Background Individual participant data

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical

More information

Treatment of Stage III Non-small Cell Lung Cancer

Treatment of Stage III Non-small Cell Lung Cancer CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Erlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche

Erlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche Erlotinib for the treatment of non-small cell lung cancer Report from the Decision Support Unit in response to additional data submitted by Roche 10 th January 2008 Part 1: A Sutton. Critique of the network

More information

Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline

Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:

More information

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with

More information

Outcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery

Outcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery Outcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery Hale B. Caglar, MD 1 ; Elizabeth H. Baldini, MD, MPH 1 ; Megan Othus, MS 2

More information

REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group Educational session Treatment of stage III non-small cell lung cancer (NSCLC) in

More information

ORIGINAL ARTICLE THORACIC ONCOLOGY

ORIGINAL ARTICLE THORACIC ONCOLOGY Ann Surg Oncol (2013) 20:1934 1940 DOI 10.1245/s10434-012-2800-x ORIGINAL ARTICLE THORACIC ONCOLOGY Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

Recent Trends in Management of Unresectable Non-Small Cell Lung Cancer (NSCLC)

Recent Trends in Management of Unresectable Non-Small Cell Lung Cancer (NSCLC) Bahrain Medical Bulletin, Vol.23, No.4, December 2001 Recent Trends in Management of Unresectable Non-Small Cell Lung Cancer (NSCLC) Jalal Al-Maskati, MBChB, ABIM * Lung cancer is a major health problem

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Lung cancer is the number one cancer cause of mortality

Lung cancer is the number one cancer cause of mortality ORIGINAL ARTICLE Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC) The Importance of Smoking History, Socioeconomic and Marital Statuses, and Sai-Hong Ignatius Ou, MD,

More information

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen. Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Suresh Ramalingam, a Chandra Belani b a Lung & Thoracic Malignancies Program, University of Pittsburgh

More information

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,

More information

Pulmonary function. Is patient potentially operable? Yes. tests 3. Yes. Pulmonary function. tests 3, if clinically indicated. Yes

Pulmonary function. Is patient potentially operable? Yes. tests 3. Yes. Pulmonary function. tests 3, if clinically indicated. Yes INITIAL EVALUATION Pathology consistent with small cell lung cancer History and physical Chest X-ray Laboratory studies to include: hematological and full chemistry panels CT chest and upper abdomen Pet

More information

Small Cell Lung Cancer* State-of-the-Art Therapy 1994

Small Cell Lung Cancer* State-of-the-Art Therapy 1994 Small Cell Lung Cancer* State-of-the-Art Therapy 1994 Daniel C. Ihde, MD In the United States, small cell lung cancer (SCLC) accounts for about 20% of all cases of lung cancer. Without treatment, tumor

More information

How To Know If You Have Small Cell Lung Cancer

How To Know If You Have Small Cell Lung Cancer Lung cancer Lung cancer TABLE 85 1. MALIGNANT PULMONARY NEOPLASMS INCIDENCE (%) Common 99 Non small cell lung cancer ~75 Adenocarcinoma ~35 Squamous cell carcinoma ~30 Large cell carcinoma ~10 Small cell

More information

SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years

SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):

More information